Pancreatic Neoplasms Clinical Trial
Official title:
Thunderbeat™ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Registry Trial
The Whipple procedure is the standard method for therapy for cancerous tumors, inflammation, and stenosis (narrowing) near the head of the pancreas. This is a prospective study to assess whether or not use of the Thunderbeat™ device may decrease blood loss and postoperative morbidity (the presence of illness or disease). The findings will then be compared to patients whose Whipple procedure will be performed using conventional dissection and hemostasis techniques.
As the pancreas is fed by many vessels, it is necessary to use lots of ligatures, clips and
sutures for hemostasis after dissection. This dissection technique is very time consuming and
requires numerous changes of instruments. The devices the investigators currently have
available for use in the operating suite are EnSeal and LigaSure. A new type of surgical
scissors that delivers ultrasonically generated frictional heat energy and electrically
generated bipolar energy simultaneously, known as the Thunderbeat™ (Olympus, Japan), is now
an available alternative for dissection and hemostasis.
Thunderbeat™ was provided FDA clearance in March 2012 for use in open, laparoscopic, and
endoscopic surgery, or in any procedure in which cutting, vessel ligation (sealing and
cutting), coagulation, grasping and dissection is performed.
The Thunderbeat™ device provides the first integration of both bipolar and ultrasonic
energies delivered simultaneously from a single multi-functional instrument. This integration
provides the surgeon the ability to rapidly cut tissue with ultrasonic energy and to create
reliable vessel seals with bipolar energy without having to change devices. The current is
provided by a special generator and contains a very high capacity with a low voltage. The
body's proteins, such as collagen and elastin, are converted so a permanently sealed zone
results. As the tissue between the branches is sealed, lateral thermic tissue damages can be
limited to a minimum. Several authors have described a tendency of reduced intraoperative
blood loss with bipolar energy devices. Other trials show reduced operating time when a
bipolar device is utilized in several surgical procedures, such as thyroid, hepatic,
urologic, hemorrhoidectomy and gynecology surgery.
Correct dissection in the operating field is very important to avert secondary bleeding or
other complications, which might cause re-operation or elevate the patients' morbidity and
mortality.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04085055 -
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
|
N/A | |
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Recruiting |
NCT05481476 -
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT02909530 -
Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses
|
N/A | |
Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT01515046 -
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
Completed |
NCT00985777 -
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
|
Phase 1 | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00178763 -
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
|
Phase 2 | |
Completed |
NCT00136669 -
Acupuncture For Pancreatic Cancer Pain
|
Phase 3 |